CLINICAL TRIALS PROFILE FOR VENTAVIS
✉ Email this page to a colleague
All Clinical Trials for Ventavis
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00235521 ↗ | Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery | Completed | Heidelberg University | N/A | 2005-05-01 | Inhaled nitrous oxide (iNO) will be compared to aerosolized iloprost (ILO) in pediatric patients after cardiac surgery with pulmonary hypertension. The hypothesis is that iloprost is more effective in preventing pulmonary hypertensive crises. |
| NCT00250640 ↗ | Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years | Completed | Bayer | 2005-04-01 | This is an observational study to monitor the continued effectiveness of Ventavis (inhaled iloprost) in the long-term. The study observes the effects and the safety of Ventavis inhalation therapy over at least 2 years and up to 4 years. A total of 54 patients from around 30 study sites in Europe will be included in the study. This observational study will collect information in patients receiving a medication that is already available on prescription in the participating countries. Ventavis is used to treat moderate cases of primary pulmonary hypertension. | |
| NCT00302211 ↗ | The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension | Terminated | Actelion | Phase 3 | 2006-02-01 | The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will also examine whether patients on sildenafil can reduce the number of iloprost inhalations from the approved 6 doses per day to 4 doses per day. |
| NCT00403650 ↗ | Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension | Completed | University of Cincinnati | Phase 4 | 2006-11-01 | This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension. |
| NCT00458042 ↗ | Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction | Terminated | United Therapeutics | Phase 4 | 2007-03-01 | The purpose of this study is to compare the effects of switching from inhaled Ventavis to intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis therapy. This study is intended to provide information on the safe transition from Ventavis to Remodulin as well as the impact intravenous Remodulin may have on overall quality of life and treatment satisfaction compared to Ventavis. |
| NCT00467896 ↗ | The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting | Terminated | Actelion | Phase 2 | 2006-09-01 | A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study" |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ventavis
Condition Name
Clinical Trial Locations for Ventavis
Trials by Country
Clinical Trial Progress for Ventavis
Clinical Trial Phase
Clinical Trial Sponsors for Ventavis
Sponsor Name
